Corcept Therapeutics (CORT) Q4 FY25 earnings call

Corcept Therapeutics reported strong Q4 FY25 results driven by its Cushing's Syndrome business, which experienced a surge in demand and successfully transitioned to a new pharmacy vendor. However, the FDA's unexpected Complete Response Letter for relacorilant in Cushing's syndrome presents a near-term challenge, while the company plans to appeal a court ruling against its Korlym patents. The oncology pipeline showed significant progress with positive Phase III ROSELLA data and a PDUFA date set for July, alongside advancing studies in MASH and ALS.